ArticleBipolar disorders2026
Trans-Tissue Effects of Hippocampus- and Blood-Derived DNA Methylation Risk Scores on Bipolar Disorder Diagnosis.
Article in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trans-Tissue Effects of Hippocampus- and Blood-Derived DNA Methylation Risk Scores on Bipolar Disorder Diagnosis.Bipolar disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBipolar disorder (BD) is a common psychiatric disorder with complex genetic and epigenetic underpinnings. This study aimed to investigate whether methylation risk scores (MRSs) derived from epigenome-wide association studies (EWASs) for BD risk in living peripheral blood and postmortem hippocampal tissues are associated with BD diagnosis across tissues.
methodsDNA methylation data were analyzed from two datasets, including living peripheral blood samples (n = 40) and postmortem hippocampal tissues (n = 63) obtained from patients with BD and unaffected controls. Two EWASs using data from blood and hippocampal samples were performed to identify differentially methylated positions (DMPs), and MRSs for BD risk in blood and hippocampal samples were calculated by aggregating methylation effects across the genome. Associations between MRSs and BD diagnosis and the potential influences of genome-wide significant (GWS) loci related to BD and health-related confounding factors, such as smoking, body mass index (BMI), and suicide, on these associations were assessed.
resultsPostmortem hippocampus-derived MRSs for BD risk were significantly associated with BD diagnosis in blood samples (R
conclusionsPostmortem hippocampus-derived MRSs may capture brain-specific epigenetic changes associated with BD pathophysiology, reflecting their diagnostic relevance in living peripheral blood. Further studies with larger sample sizes and multitissue approaches are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.